Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

Mohammed Alcharakh; Seongseok Yun; Yimin Dong; Nicole D. Vincelette; Madiha Daud; Saima Manzoor; Irbaz Bin Riaz; Faiz Anwer

doi:10.2217/imt-2015-0023

Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

Mohammed Alcharakh, Seongseok Yun, Yimin Dong, Nicole D. Vincelette, Madiha Daud, Saima Manzoor, Irbaz Bin Riaz, Faiz Anwer

Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph⁺) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

Original language	English (US)
Pages (from-to)	847-852
Number of pages	6
Journal	Immunotherapy
Volume	8
Issue number	8
DOIs	https://doi.org/10.2217/imt-2015-0023
State	Published - Jul 2016

Keywords

Biphenotypic acute leukemia
CD19
blinatumomab

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2015-0023

Cite this

@article{82342fe25f0f451aa135624ad1f8d033,

title = "Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia",

abstract = "Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.",

keywords = "Biphenotypic acute leukemia, CD19, blinatumomab",

author = "Mohammed Alcharakh and Seongseok Yun and Yimin Dong and Vincelette, {Nicole D.} and Madiha Daud and Saima Manzoor and Riaz, {Irbaz Bin} and Faiz Anwer",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = jul,

doi = "10.2217/imt-2015-0023",

language = "English (US)",

volume = "8",

pages = "847--852",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

TY - JOUR

T1 - Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

AU - Alcharakh, Mohammed

AU - Yun, Seongseok

AU - Dong, Yimin

AU - Vincelette, Nicole D.

AU - Daud, Madiha

AU - Manzoor, Saima

AU - Riaz, Irbaz Bin

AU - Anwer, Faiz

PY - 2016/7

Y1 - 2016/7

N2 - Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

AB - Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

KW - Biphenotypic acute leukemia

KW - CD19

KW - blinatumomab

UR - http://www.scopus.com/inward/record.url?scp=84978938005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978938005&partnerID=8YFLogxK

U2 - 10.2217/imt-2015-0023

DO - 10.2217/imt-2015-0023

M3 - Article

C2 - 27381683

AN - SCOPUS:84978938005

SN - 1750-743X

VL - 8

SP - 847

EP - 852

JO - Immunotherapy

JF - Immunotherapy

IS - 8

ER -

Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this